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A Novel Genetic Selection System for Improved
Enantioselectivity of Bacillus subtilis Lipase A
Ykelien L. Boersma,[a] Melloney J. Drçge,[b] Almer M. van der Sloot,[c] Tjaard Pijning,[d]
Robbert H. Cool,[a] Bauke W. Dijkstra,[d] and Wim J. Quax*[a]
Introduction
Enzymes are powerful tools for the industrial production of
pharmaceuticals and their intermediates. They are capable of
performing highly regioselective and/or enantioselective re-
ACHTUNGTRENNUNGactions, and can accelerate reaction rates by orders of magni-
tude.[1,2] However, most applications of enzymes do not rely on
the natural reactions they catalyze, but use non-natural sub-
strates. Wild-type enzymes are often not optimal catalysts for
these applications because of poor substrate specificity, low
stability or insufficient (enantio-)selectivity for the cost-effective
production of a particular product. In this respect, directed
evolution has emerged as an important method to make en-
zymes more suitable as industrial biocatalysts.[3]
In directed evolution experiments the successful identifica-
tion of improved variants strongly depends on the availability
of effective screening or selection methods.[4] Screening is
widely applied as a first selection tool; however, the probing
of the enantioselectivity of lipases and esterases depends on
time-consuming assays.[5] As an alternative, in vivo selection
strategies can be used that exploit conditions that favor the
exclusive survival of desired variants. Consequently, uninterest-
ing variants are never seen, and larger mutant libraries can
easily be evaluated, even up to sizes of 1010 variants.[6, 7]
A powerful selection method is based on linking cell survival
to the desired enzymatic activity. The general strategy for such
a selection system involves the introduction into the host cells
of a stringent metabolic requirement for the desired activity.
Plasmids that encode a mutant library of the protein of interest
are introduced into the selection host. Next, selective growth
conditions are imposed in such a way that only those cells
that express variants of the protein of interest with the desired
activity are viable.[3, 7,8]
Many examples of genetic selections for improved activity
are available.[7–12] Often substrate mimics are used in the
design of an in vivo selection method for a specific reaction to
fulfill the metabolic requirement.[13] These mimics should be
soluble in water, and they and their products should not inter-
fere with the cellular environment.
Our aim is to develop an enantioselective lipase for the pro-
duction of enantiopure 1,2-O-isopropylidene-sn-glycerol (IPG),
a precursor in the synthesis of b-adrenoceptor antagonists.
Previously, we have shown that lipase A (LipA) of Bacillus sub-
ACHTUNGTRENNUNGtilis 168 is capable of hydrolyzing butyrate esters of IPG, al-
though hardly any enantiopreference was observed (ee value
of 20.3% for (R)-()-IPG).[14] Since the desired enantiomer is
(S)-(+)-IPG, we decided to apply directed evolution to develop
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In directed evolution experiments, success often depends on the
efficacy of screening or selection methods. Genetic selections
have proven to be extremely valuable for evolving enzymes with
improved catalytic activity, improved stability, or with altered
substrate specificity. In contrast, enantioselectivity is a difficult
parameter to select for. In this study, we present a successful
strategy that not only selects for catalytic activity, but for the first
time also for enantioselectivity, as demonstrated by the selection
of Bacillus subtilis lipase A variants with inverted and improved
enantioselectivity. A lipase mutant library in an aspartate auxo-
troph Escherichia coli was plated on minimal medium that was
supplemented with the aspartate ester of the desired enantiomer
(S)-(+)-1,2-O-isopropylidene-sn-glycerol. To inhibit growth of less
enantioselective variants, a covalently binding phosphonate ester
of the opposite (R)-()-1,2-O-isopropylidene-sn-glycerol enantio-
mer was added as well. After three selection rounds in which the
selection pressure was increased by raising the phosphonate
ester concentration, a mutant was selected with an improved
enantioselectivity increased from an ee of 29.6% (conversion
23.4%) to an ee of +73.1% (conversion 28.9%) towards the (S)-
(+)-enantiomer. Interestingly, its amino acid sequence showed
that the acid of the catalytic triad had migrated to a position
ACHTUNGTRENNUNGfurther along the loop that connects b7 and aE; this shows that
the position of the catalytic acid is not necessarily conserved in
this lipase.
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a LipA variant with a high (inverted) enantioselectivity towards
(S)-(+)-IPG. The three-dimensional structure of LipA[15] suggest-
ed that residues 132 to 136 would be good targets for a direct-
ed evolution approach even though Asp133 is one of the cata-
lytic triad residues. These residues were mutated and the
mutant library was transformed to E. coli K-12 PA340/T6, a
strain in which both pathways for aspartate synthesis have
been knocked out.[16] The E. coli knock-out was plated onto se-
lective minimal medium plates, supplemented with enantio-
pure (S)-(+)-IPG that had been esterified to l-aspartate. Only
those LipA variants expressed in the periplasm that could hy-
drolyze this aspartate ester were able to provide the aspartate
that was needed for bacterial growth. To avoid growth of bac-
teria that express less enantioselective variants, the stringency
of the selection was increased by adding a phosphonate ester
of the undesired IPG enantiomer to covalently inhibit variants
with some activity against the (R)-()-IPG enantiomer. Mutants
with an improved enantioselectivity towards (S)-(+)-IPG were
selected. This selection strategy for improved enantioselectivity
might be generally applicable as well to other hydrolases that
are expressed in the periplasm.
Results and Discussion
Construction of the mutant library
Cassette mutagenesis was applied to construct a saturated
mutant library directed towards amino acids 132 to 136 of
mature LipA. The primer sequences resembled the lipA se-
quence by approximately 80%. Sequence analysis of 13 clones
revealed that the percentage of both single and double-mutat-
ed amino acids was 31%. Two clones showed deletions, while
two other clones had no amino acid mutation. After transfor-
mation of E. coli TG-1, a mutant library that consisted of 3.5I
104 colonies was obtained. This should be more than sufficient
to obtain all possible single mutations at the amino acid level.
This library was used for the transformation of the aspartate
auxotroph E. coli K-12 PA340/T6.
Dual selection
To examine the functionality of the IPG aspartate substrate
mimic, its hydrolysis by purified wild-type LipA was determined
in the IPG assay and compared with the hydrolysis of the sub-
strate of interest IPG butyrate. The enzyme converts both sub-
strates to a similar degree: 29.4% for IPG butyrate versus
21.8% for the aspartate ester. Wild-type LipA hydrolyzes the
commonly used substrate IPG butyrate with an enantiomeric
excess (ee) of 12.9% 1.6 of the (R)-()-enantiomer. IPG as-
partate is also hydrolyzed, with a somewhat lower enantiomer-
ic excess of 5.51.1% towards the (R)-()-enantiomer. No
statistically significant difference was observed in enantioselec-
tivity towards the substrates (p<0.001). These results indicate
that IPG aspartate can be used as a mimic substrate.
To introduce a dual selection step, soluble IPG phosphonate
inhibitors were used (Scheme 1). To assess the inhibitory effect
of the IPG phosphonate esters, an inhibition assay was per-
formed by using purified wild-type LipA according to ref. [17].
The t50 of inhibition was 10 min for both enantiomers. Further-
more, transformed wild-type LipA was plated on minimal
medium supplemented with the IPG phosphonate ester and
on LB agar plates. The latter showed approximately 2500 colo-
nies after overnight incubation, while only a few small colonies
appeared on the phosphonate plates after 5 days of incuba-
tion. These results indicate that the phosphonate inhibitor
limits rather than completely abolishes growth. This allows the
use of phosphonate inhibitors in directed evolution experi-
ments.
Scheme 1. A) Chemical structure of 1,2-O-isopropylidene-sn-glycerol (IPG). B) Chemical structure of the aspartate ester of IPG. C) Chemical structure of the
soluble phosphonate inhibitors. Note that the inhibitor is enantiopure at the chiral atom of the IPG molecule and racemic at the phosphorous atom. The
ACHTUNGTRENNUNGabsolute configuration of IPG changes upon attachment to the phosphorous atom or upon ester bond formation.
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Selection on selective minimal
medium
E. coli K-12 PA340/T6-competent
cells were transformed with the
mutant library and, as a control,
with wild-type LipA. Approxi-
mately 2500 colonies appeared
per plate after overnight incuba-
tion on LB agar plates. On plates
supplemented with either aspar-
tate or the aspartate ester, ap-
proximately 1500 colonies ap-
peared after two days. On plates
supplemented with the phos-
phonate inhibitor in addition to
the aspartate ester, colonies also
appeared after two days, al-
though their number was reduced to approximately 1000 colo-
nies. Negative control plates showed approximately 100 small
colonies after 5 to 10 days of incubation. After the second
round of selection, approximately 750 colonies appeared on
plates supplemented with both the inhibitor and the aspartate
ester, while after the third round approximately 400 colonies
were found.
At the end of each round after two days of growth, the 50
largest colonies were chosen from the plates supplemented
with both the aspartate ester and the phosphonate inhibitor,
and their LipA proteins were isolated from the periplasmic
fraction. Table 1 shows the catalytic activities, enantioselectivi-
ties (expressed as enantiomeric excess ee and E value) and the
mutations that were introduced into the variants.
The first round of selection was designed in such a way that
conditions were not too stringent. All selected variants showed
an (inverted) enantioselectivity towards (S)-(+)-IPG. However,
under these mild conditions not many variants with a signifi-
cantly improved enantioselectivity (ee >+30%) were found.
Ultimately, two more improved variants were sequenced; one
variant had only one mutation, I135F, while the other variant
had mutations A132P/M134Q.
The enantioselectivity of the best variant (A132P/M134Q) in-
creased in subsequent selection rounds with higher selection
pressure, from an ee value of +34% after the first round, to an
ee value of +73% after the third selection round. Sequence
analysis revealed that all 5 residues in the region of 132 to 136
were prone to mutation, and residue 134 showed the highest
mutation frequency.
Some colonies were picked from the plates that were sup-
plemented with (S)-()-IPG aspartate ester as well ; these had
activities and enantioselectivities that were comparable to
those of wild-type LipA (conversion approximately 20%, ee
ACHTUNGTRENNUNGapproximately 25% towards (R)-()-IPG).
Interestingly, the catalytic residue Asp133 was prone to mu-
tation as well, without apparent effect on the viability of the
clones. Therefore, the mutant found in the third selection
round, D133A/V136D, was subjected to further analysis.
Characterization of the D133A/V136D mutant
The expression of variant D133A/V136D in the periplasm was
examined by SDS-PAGE and western blot (Figure 1), and was
found to be similar to wild-type LipA. D133A/V136D had a
ACHTUNGTRENNUNGcatalytic activity that was comparable to that of the wild-type
enzyme (conversion of 28.9% versus 23.4% of wild-type LipA).
In contrast, its KM for (S)-(+)-IPG was significantly lowered, and
its KM for (R)-()-IPG was significantly increased (Table 2, p<
0.05) ; this resulted in an improved enantioselectivity with an
ee of 73.1% 0.7 towards (S)-(+)-IPG (E value of 8.5).
An intriguing question is why the mutation of Asp133, one
of the catalytic triad residues, to an alanine does not abolish
catalytic activity. Inspection of the 3D structure of LipA,[15]
Table 1. Enantioselective hydrolysis of racemic esters of IPG butyrate by periplasmic fractions of selected LipA
variants (n=3).
Variant Conversion (%) ee (%) E[a] Enantiomer formed in excess Mutation
WT LipA 23.41.1 29.60.5 1.8 (S)-()-IPG
1st round
1 36.61.0 +34.40.7 2.4 (S)-(+)-IPG A132P, M134Q
2 6.70.6 +43.20.8 2.6 (S)-(+)-IPG I135F
2nd round
3 7.22.5 +68.70.9 5.7 (S)-(+)-IPG D133N
4 15.21.2 +62.51.2 4.9 (S)-(+)-IPG A132T, M134T
5 21.20.9 +55.71.0 4.1 (S)-(+)-IPG D133E, M134R
6 19.70.8 82.52.5 12 (S)-(+)-IPG D133G, M134L, I135N
7 23.41.3 61.51.8 5.1 (S)-(+)-IPG D133Q, M134L, I135T
3rd round
8 28.90.5 73.10.7 8.5 (S)-(+)-IPG D133A, V136D
[a] E values were calculated by using the programme Selectivity by K. Faber and H. Hoenig, http://www.orgc.
TUGraz.at/
Figure 1. Determination of the expression levels of wild-type LipA and var-
iant D133A/V136D. Left panel : Expression of wild-type LipA (lane 3) and var-
iant D133A/V136D (lane 4) in the periplasm of E. coli HB2151 on SDS-PAGE
(12%). An empty E. coli HB2151 strain (lane 2) was taken as a control, as well
as purified lipase (lane 5). The arrow indicates lipase; note that lipase in the
periplasmic fractions runs slightly higher on the gel due to a (His)6-tag. The
marker is shown in lane 1. Protein (25 mg) was loaded onto the gel. Right
panel : Expression of wild-type LipA (lane 3) and variant D133A/V136D
(lane 4) in the periplasm of E. coli HB2151 on western blot (detection by
using aLipA). An empty E. coli HB2151 strain (lane 2) was taken as a control,
as well as purified lipase (lane 5). The marker is shown in lane 1.
Table 2. KM determination of variant D133A/V136D (n=3)
Enzyme KM [mm] butyrate ester of
()-IPG (+)-IPG
WT LipA 0.530.33 1.050.10
LipA D133A/V136D 1.910.41 0.360.22
Statistical significance of differences: p<0.05.
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shows that the role of Asp133 might be taken over by the as-
partate introduced at position 136 in the D133A/V136D variant
(Figure 2).
To test this hypothesis, the double mutant D133AV136A was
constructed and expressed in the periplasm of E. coli HB2151.
The mutant appeared to have no activity on IPG butyrate. In
contrast, changing residue 136 into an aspartate, as in the
D133A/V136D double mutant, restores activity; this demon-
strates that Asp136 can take over the role of Asp133. In the
case of mutant D133A/V136D, the alanine at position 133 is
unable to stabilize the positive charge of His156. Since the
double mutant does show appreciable activity, it is likely that
the aspartate residue that was introduced at position 136
takes over the role of Asp133. Modeling shows that indeed an
aspartate residue at position 136 can interact with His156 in
such a way that the His156 side chain can also still interact
with the Ser77 side chain (Figure 2B).
Conclusions
In the past, genetic selections such as presented here have
been successful in obtaining enzymes with improved catalytic
activity, increased stability, or altered substrate specificity. Yet,
enantioselectivity has proven to be a difficult property to
select for. Some indirect screening methods for enantioselec-
tivity based on bacterial growth have been described.[18–20]
However, these screening methods involve the individual ex-
amination of variants, and are therefore cumbersome and
often time consuming. In contrast, selection strategies encom-
pass the generation of a large number of variants of which
only the best ones are retained, thus the amount of work in-
volved in the characterization of the obtained variants is re-
duced. To be able to select directly for enantioselectivity in ad-
dition to catalytic activity, we have developed a novel genetic
selection system that allows the analysis of larger libraries
compared to the previously described indirect screening meth-
ods. Moreover, the addition of a phosphonate ester of the
ACHTUNGTRENNUNGundesired enantiomer, which covalently inhibits the enzyme
ACHTUNGTRENNUNGreduces the number of uninteresting variants.
Our selection system is based on the growth of an aspartate
auxotroph E. coli strain; the imposed selection pressure is in-
creased by raising the concentration of the phosphonate inhib-
itor. After the third round, no further improvement of the
enantioselectivity was observed, possibly because of the small
library of only five randomized amino acids. The variant with
the highest enantioselectivity was found in the second selec-
tion round (D133G/M134L/I135N). It showed an ee of +82.1%
(E value of 12), but its activity was less than that of wild-type
LipA (conversion of 19.7% versus 23.4% for LipA), and, there-
fore, it was not further analyzed. The best mutant from the
third selection round was variant D133A/V136D. It combines a
20–25% enhanced conversion rate with an enantioselectivity
that is improved from an ee value of 29.6% for the wild-type
enzyme, to an ee of +73.1% for the desired substrate. It is
likely that by using larger libraries or by applying DNA shuf-
fling[21] or CASTing[22] variants with even higher enantioselectiv-
ity might be generated.
A surprising result of our work was the finding that the cata-
lytic triad residue Asp133 became mutated as well (to Asn or
Glu), without completely destroying the catalytic activity of the
enzyme. Nevertheless, these mutations are not unique. In
phospholipase A2 it has also been shown that an Asn residue
can take over the role of the Asp as a catalytic acid,[23] and a
Glu instead of an Asp is the catalytic acid in some other a/
b hydrolases.[24] Thus some variability is possible with respect
to the nature of the acidic catalytic residue without a drastic
effect on the activity of the enzyme.
However, not only the nature of the acidic catalytic residue
can vary in the a/b hydrolase fold enzymes, but also its topo-
logical location. While the nucleophile and the general base
histidine are located after b-strand 5 and b-strand 8, respective-
ly, the acidic catalytic residue has in some cases been found
after strand b6 instead of after b7.[25] In this work, two variants
were obtained with another topological variation of the cata-
lytic acid, which moved by two or three sequence positions.
The significant activity of mutants D133G/M134L/I135N and
D133A/V136D suggests that loop 133–136 has sufficient plasti-
city to stabilize a productive conformation of the His156 side
chain. In the D133A/V136D mutant, the absence of a large side
chain at position 133 allows an Asp at position 136 to easily
assume a side-chain rotamer conformation that brings it within
hydrogen-bonding distance of the His156 side chain. No major
conformational changes are required, although a slight read-
justment of the His156 side chain to improve its interaction
with Asp136 cannot be excluded. In the D133G/M134L/I135N
mutant, a productive interaction with the His side chain can
also be modeled, although the required conformational
changes are somewhat larger. So far, this positional variation
seems only to occur in LipA; a one-to-all fit[26] with D133A/
V136D as a search model against other a/b hydrolase fold
ACHTUNGTRENNUNGenzymes did not reveal any other enzymes with such a reposi-
tioned catalytic acid as in D133A/V136D.
Both variants have an improved enantioselectivity towards
(S)-(+)-IPG. It is, however, difficult to find a possible molecular
explanation for this improved enantioselectivity. From the 3D
structure of wild-type B. subtilis LipA, it is clear that the active-
site cleft is relatively open, and both IPG enantiomers can be
accommodated equally well.[14] Mutation of residues 133–136
might lead to some adaptation of the His156 side-chain orien-
tation, but the exact effect on the binding of the two IPG en-
antiomers remains hard to assess in the absence of detailed
Figure 2. Model of wild-type LipA compared to mutant D133A/V136D. A) Po-
sitioning of catalytic residues in wild-type LipA. B) Positioning of catalytic
residues in variant D133A/V136D, in which the acid is repositioned.
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structural and dynamic information on the mutants and their
interaction with the IPG enantiomers.
The genetic-selection system as presented here has led to
the successful identification of improved LipA variants. A disad-
vantage of the system could be the required translocation of
the protein to the periplasm of the E. coli auxotroph, which is
required in order to convert the substrate mimic. Theoretically,
this might limit a broad applicability of this method. We have,
however, recently demonstrated that even an intracellular car-
boxyl esterase (CesA) can be translocated to the periplasm
solely by inserting a specific signal sequence.[27] CesA is also
active on IPG-aspartate esters, and thus the same selection
strategy as described here might be applied to CesA as well. In
summary, the presented growth selection system might be
generally applicable in the selection of more enantioselective
hydrolase variants that can be translocated to the periplasmic
space.
In conclusion, a novel bacterial growth system was devel-
oped that is suitable for the enantioselective selection of hy-
drolytic enzymes. The applicability of this strategy was demon-
strated by the selection of lipase variants with an inverted and
improved enantioselectivity. Since this system can be applied
for the enantioselective selection of variants of other hydrolas-
es as well, we believe we have established a strategy that is
generally applicable, and that offers a new perspective for the
evolution of enzyme enantioselectivity.
Experimental Section
Plasmids, bacterial strains and media : E. coli K-12 PA340/T6 (thr-1,
leuB6(Am), fhuA2, lacY1, glnV44(AS), gal-6, l , gdhA1, hisG1(Fs),
rfbD1, galP63, D(gltB-gltF)500, rpsL9, malT1(lR), xylA7, mtlA2,
DargH1, thi-1) was kindly provided by the E. coli Genetic Stock
Center (Yale University, New Haven, USA). E. coli HB2151 (K12 D-
ACHTUNGTRENNUNG(lac-pro), ara, nalr, thi/F’, proAB, laqIq, lacZD-M15) and pCANTAB 5E
were purchased from Pharmacia (Amersham Pharmacia Biotech,
Uppsala, Sweden). 2xTY medium, which contained Bactotrypton
(1.6% v/w), Bacto yeast extract (1% v/w) and NaCl (0.5% v/w) was
used. As antibiotic agents ampicillin (100 mgmL1) and streptomy-
cin (100 mgmL1; Duchefa Biochemie, Haarlem, The Netherlands)
were used. M8 minimal medium, which contained Na2HPO4·7H2O
(4 gL1), KH2PO4 (15 gL
1) and NaCl (2.5 gL1) was used.
Chemicals : The aspartate and butylphosphonate esters of both
IPG enantiomers were synthesized by Syncom BV (Groningen, The
Netherlands; Scheme 1). Butyrate esters of both IPG enantiomers
were kindly provided by Prof. M. T. Reetz (Max-Planck Institut fPr
Kohlenforschung, MPlheim, Germany). Supplemental amino acids
(Thr, Arg, Leu, His, Asp), thiamine, MgSO4 and CaCl2 were pur-
chased from Sigma–Aldrich.
Construction of the mutant library : The LipA-encoding gene was
cloned into the phagemid pCANTAB 5E, downstream of a modified
g3p signal sequence, as described previously.[17] To introduce a
XbaI restriction site, a silent mutation was introduced at base pair
position 423 of the lipA gene by using LipXbaIFor (Life Technolo-
gies, Paisley, UK): 5’-TTACTTATCTAGATTAGATGGTGCTGA-3’ and
LipXbaIRev: 5’-CTAGCACCATCTAATCTAGATAAGTAA-3’ as primers.
The XbaI restriction site is indicated in bold italics. To construct the
mutant library in the region of residues 132 to 136, the following
primers were used: CanHindFor (Life Technologies, Paisley, UK) 5’-
CCATGATTACGCCAAGCTTTGGAGCC-3’ (HindIII restriction site in
bold italics) and 00B470Rev (Eurogentec, Groningen, The Nether-
lands) 5’-TAATCTAGATAAGTAATTCAT867665765657887ACTGCTGT ACHTUNGTRENNUNG -
ACHTUNGTRENNUNG ATGGA-3’ (XbaI restriction site in bold italics; 5=80% T; 6=80%
A; 7=80% C; 8=80% G; the remaining 20% is an equal mixture
of the other three bases). Recombinant DNA procedures were car-
ried out as described by Sambrook et al.[28] Plasmid DNA was pre-
pared by using the Qiaspin miniprep kit (Qiagen) and DNA purifi-
ACHTUNGTRENNUNGcation was performed by using the Qiaquick gel extraction kit
(Qiagen). The library was amplified from B. subtilis 168 chromoso-
mal DNA as a template by using Pfu polymerase (Stratagene). The
gene fragment was digested with HindIII and XbaI (New England
Biolabs, Ipswich, MA, USA), and cloned in E. coli TG-1 into the Hin-
dIII and XbaI sites of the pCANTABLip-CH plasmid.[17] The obtained
mutant library was sequenced to assess the mutation ratio. The
LipA variant D133A/V136A was constructed by using QuikchangeR
PCR (Stratagene) with the following primers: LipDAVAFor 5’-CATT-
TACAGCAGTGCCGCAATGATTGCCATGAATTACTTATCCAGA-3’ (Oper-
ACHTUNGTRENNUNGon, Cologne, Germany) and LipDAVARev 5’-TCTGGATAAGTAATT-
CATGGCAATCATTGCGGCACTGCTGTAAATG-3’.
Selection on selective minimal medium : E. coli K-12 PA340/T6
cells were made chemically competent and transformed with
mutant plasmid DNA and wild-type LipA (50 ng).[28] A negative con-
trol was investigated as well. Transformation mixtures were starved
by incubation in 0.9% NaCl for 2 h at 37 8C, and plated onto selec-
tive M8 minimal medium agar (1.6%) plates. The medium was sup-
plemented with MgSO4 (1 mm), CaCl2 (0.1 mm), essential amino
acids (Thr, His, Arg, Leu; 20 mgmL1) and thiamine (1 mgmL1). The
aspartate ester of (R)-()-IPG or (S)-(+)-IPG (1.5 mm) was added to
the agar plates as the sole aspartate source,. To select for enantio-
selective variants, butylphosphonate ester of the undesired IPG en-
antiomer (1.5 mm) was added to the medium as well to eliminate
nonselective variants or variants that were selective for the oppo-
site enantiomer. Approximately 2500 viable E. coli K-12 PA340/T6
cells that contained the mutant plasmids were plated onto each
plate. We used LB, Asp (20 mgmL1; Sigma) and Min (no aspartate
or esters present) as control plates. Plates were incubated at 30 8C.
Upon appearance 50 colonies were picked, and their periplasmic
fraction was isolated and used in the 1,2-O-isopropylidene-sn-glycol
ester assay as described below. The remaining colonies were har-
vested and plated again onto selective minimal medium with an in-
creased concentration of phosphonate ester (3 mm) for a second
round of selection. For a third round of selection, the phosphonate
ester concentration was increased to 7.5 mm. The plasmid DNA was
isolated from bacteria that express a lipase variant with an inverted
enantioselectivity, and sequenced to examine the ACHTUNGTRENNUNGmutation(s).
Isolation of the periplasmic fraction : E. coli K-12 PA340/T6 was
grown in 50-mL tubes that contained 2xTY medium (10 mL), ampi-
cillin and isopropyl-b-d-galactopyranoside (IPTG, 1 mm). The tubes
were incubated at 37 8C at 250 rpm for 16 h. The OD600 was record-
ed and the cells were harvested and resuspended in Tris–HCl
buffer (10 mm, pH 7.4). After centrifugation, the cells were resus-
pended in buffer (200 mL) that contained Tris–HCl (10 mm, pH 8.0),
25% (v/w) sucrose, ethylene diamine tetraacetic acid (EDTA, 2 mm)
and lysozyme (0.5 mgmL1, Sigma–Aldrich). After incubation on ice
for 20 min, buffer (50 mL) that contained Tris–HCl (10 mm, pH 8.0),
20% (v/w) sucrose and MgCl2 (125 mm) was added. The suspen-
sion was centrifuged and the supernatant that contained the peri-
plasmic fraction was isolated and used as the enzyme solution in
the IPG ester assay. The protein content of this fraction was deter-
mined by using the Bradford assay in triplicate with bovine serum
albumin (BSA) as a standard (Pierce, Rockford, Illinois, USA).
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1,2-O-Isopropylidene-sn-glycerol ester assay : Periplasmic frac-
tions were diluted with 3-(N-morpholino)propanesulfonic acid
(MOPS) buffer (0.07m, pH 7.5), that contained 0.2% (v/w) BSA, to a
final volume of 100 mL. References were diluted correspondingly,
but contained no enzyme solution. The esters of IPG (1 mm) were
dissolved in MOPS buffer (10 mL, 0.07m, pH 7.5), that contained
Tween 80 (14.3% v/w), and diluted to 50 mL with MOPS buffer.
Substrate solution (500 mL) was added to the enzyme solution and
the final mixture was incubated in a water bath at 32 8C. After 16 h
incubation, a saturated NaCl solution (400 mL) and internal stan-
dard solution (10 mL, racemic hex-3-en-1-ol, 5 mgmL1 in assay
buffer) were added to the sample solution and the aqueous solu-
tion was extracted twice with ethyl acetate (1 mL). GC analysis was
performed as described by Drçge et al.[29] Enantiomeric excesses,
ee, and the optical purities of the product fractions were calculated
according to Chen et al.[30] All data were expressed as mean  sd.
Enantioselectivities E were calculated by using the program Selec-
tivity (K. Faber, H. Hoenig. http://www.orgc.TUGraz.at). The statisti-
cal significance of the differences in enantiomeric preference was
tested at a significance level of p<0.05 by using a two-tailed
ACHTUNGTRENNUNGStudent’s t-test.
Determination of KM : Because of higher expression levels, E. coli
HB2151 was used in this case for overexpression and was grown
for 16 h at 37 8C in 2xTY medium (1 L) that was supplemented with
ampicillin (100 mgmL1) and 1 mm IPTG. The periplasmic fraction
was isolated as described above. The total protein content was de-
termined by performing a Bradford assay. To determine the expres-
sion level of LipA and variant D133A/V136D, SDS-PAGE was per-
formed on a 12% separating and a 3% stacking gel (Invitrogen,
Groningen, The Netherlands). Molecular mass markers were pur-
chased from Invitrogen. After electrophoresis, proteins were blot-
ted to nitrocellulose and immunostained with a rabbit antiserum
against LipA. Detection of the antibody was performed with horse
radish peroxidise (HRP)-conjugated antibodies against rabbits. To
obtain a KM value, the IPG assay was performed in triplicate. The KM
value for each enantiomer was obtained by fitting the experimen-
tal data from Eadie–Hofstee plots. The mean and sd of three meas-
urements were calculated.
Structural alignment of variant D133A/V136D with other a/b hy-
drolase fold enzymes : In variant D133A/V136D, the position of
the catalytic acid was shifted towards the end of the loop that con-
nects b7 and aE. To examine whether this was a unique feature
within the family of a/b hydrolases, a one-to-all fit was made by
using TOPOFIT.[26] This method analyzed the similarity in protein
structure by using 3D Delaunay triangulation patterns that were
derived from a backbone representation.[31] A structural alignment
of the repositioned catalytic site was made by using the SwissProt
PDB viewer. The structures were superimposed by using the cata-
lytic His residue and the Ca and Cb atoms of the other two catalyt-
ic residues; the final overlay figure was constructed by using
PyMOL version 0.99 (DeLano Scientific, Palo Alto, CA, USA).
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